bluebird bio, Inc. (NASDAQ:BLUE) Receives $5.87 Average PT from Brokerages

Shares of bluebird bio, Inc. (NASDAQ:BLUE) have been given an average rating of “Hold” by the twelve brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $5.87.

A number of research firms have recently commented on BLUE. William Blair reissued a “market perform” rating on shares of bluebird bio in a report on Tuesday, January 9th. StockNews.com raised shares of bluebird bio to a “sell” rating in a report on Thursday, March 28th. Wells Fargo & Company dropped their target price on shares of bluebird bio from $4.00 to $3.00 and set an “equal weight” rating for the company in a report on Wednesday, March 27th. HSBC dropped their target price on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a report on Tuesday, March 5th. Finally, Wedbush dropped their target price on shares of bluebird bio from $1.72 to $1.68 and set a “neutral” rating for the company in a report on Tuesday, March 19th.

Hedge Funds Weigh In On bluebird bio

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Aigen Investment Management LP acquired a new position in shares of bluebird bio in the third quarter worth approximately $34,000. Johnson Investment Counsel Inc. acquired a new position in shares of bluebird bio in the third quarter worth approximately $40,000. Dynamic Technology Lab Private Ltd acquired a new position in bluebird bio in the fourth quarter valued at approximately $37,000. Sequoia Financial Advisors LLC acquired a new position in bluebird bio in the fourth quarter valued at approximately $37,000. Finally, Enterprise Bank & Trust Co acquired a new position in bluebird bio in the first quarter valued at approximately $38,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Stock Down 6.5 %

Shares of bluebird bio stock opened at $0.95 on Tuesday. The company has a market capitalization of $104.27 million, a price-to-earnings ratio of -1.29 and a beta of 0.74. bluebird bio has a 12-month low of $0.88 and a 12-month high of $5.53. The firm’s 50-day moving average price is $1.26 and its two-hundred day moving average price is $2.02.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.